R3 Stem Cell Publishes Consumer Guide on Stem Cells for Premature Ovarian Failure

R3 Stem Cell published a Consumer Guide on Stem Cell Therapy for Premature Ovarian Failure. The Guide reviews the basics of how stem cells work for POF.

BEVERLY HILLS, CALIFORNIA, USA, June 3, 2024 /EINPresswire.com/ -- R3 Stem Cell has published a Consumer Guide on Stem Cell Therapy for Premature Ovarian Failure. The Guide reviews the basics of how stem cells and exosomes work for POF, the latest research, and what to expect with a regenerative procedure. The Guide is available as a free download at https://r3stemcell.com/pof-guide.

Conventional treatments for POF are often not able to regenerate and repair ovarian tissue and follicular activation significantly. For women who desire conception spontaneously or with IVF, failure with conventional treatments is disappointing and entails a significant time factor with it. Stem cell therapy for POF is turning out to be an excellent opportunity for individuals to achieve functional restoration of the ovaries.

R3 Stem Cell offers stem cell treatment for POF in several countries including Mexico, Pakistan, India and the Philippines. It is a relatively new area for regenerative medicine, and new research continues to show effectiveness for premature ovarian failure. POF affects approximately 1% of women of childbearing age. Although 5–10% of patients may conceive naturally, conventional infertility treatments, including assisted reproductive technology, often prove ineffective for the majority.

R3 Stem Cell has seen success with the procedure, with a significant amount of women achieving either spontaneous pregnancies or subsequent success with in vitro fertilization. The stem cell clinics in Mexico are located in Cancun and Tijuana.

According to R3 CEO Dr. David Greene, MD, PhD, MBA, "The R3 research team wrote a wonderful

literature review showcasing all of the clinical trials around the world regarding stem cells for POF. Results have been consistently promising, and our procedures have done well too." The paper is located here: https://pubmed.ncbi.nlm.nih.gov/36520408/



It has been demonstrated in several investigations that umbilical cord mesenchymal stem cells can repair compromised ovarian function by producing cytokines and other factors involved in proliferation and tissue formation. When R3 Stem Cell performs the POF procedure, a transvaginal ultrasound probe guides the cannula into each ovary, where stem cells and exosomes are injected. It's a safe, effective and well tolerated procedure.

Currently, R3 Stem Cell offers free consultations for women to see if they are a candidate for the procedure. To set that up, please call +1 (844) GET-STEM, which is (844) 438-7836. R3 Stem Cell has Centers of Excellence in six countries, and has performed over 24,000 stem cell procedures in the past decade.

> The R3 research team wrote a literature review showcasing all of the clinical trials around the world regarding stem cells for POF. Results have been promising, and our procedures have done well too."
>
> *David Greene, MD, PhD, MBA*

David Greene, MD, PhD, MBA
R3 Stem Cell International
+1 (888) 988-0515
email us here
Visit us on social media:
Facebook
YouTube



Stem Cell Reviews and Reports
https://doi.org/10.1007/s12015-022-10493-y

The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure

Amna Umer[1] · Nasar Khan[1,2] · David Lawrence Greene[1,2] · Umm E. Habiba[1] · Sabiha Shamim[1] · Asma Umer Khayam[3]

Accepted: 10 December 2022

Abstract
Premature ovarian failure (POF) affects 1% of women under 40, leading to infertility. The clinical symptoms of the POF include hypoestrogenism, lack of mature follicles, hypergonadotropinism, and amenorrhea. POF can be caused due to genetic defects, autoimmune illnesses, and environmental factors. The conventional treatment of POF remains a limited success rate. Therefore, an innovative treatment strategy like the regeneration of premature ovaries by using human umbilical cord mesenchymal stem cells (hUC-MSCs) can be a choice. To summarize all the theoretical frameworks for additional research and clinical trials, this review article highlights all the results, pros, and cons of the hUC-MSCs used to treat POF. So far, the data shows promising results regarding the treatment of POF using hUC-MSCs. Several properties like relatively low immunogenicity, multipotency, multiple origins, affordability, convenience in production, high efficacy, and donor/recipient friendliness make hUC-MSCs a good choice for treating basic POF. It has been reported that hUC-MSCs impact and enhance all stages of injured tissue regeneration by concurrently stimulating numerous pathways in a paracrine manner, which are involved in the control of ovarian fibrosis, angiogenesis, immune system modulation, and apoptosis. Furthermore, some studies demonstrated that stem cell treatment could lead to hormone-level restoration, follicular activation, and functional restoration of the ovaries. Therefore, all the results in hand regarding the use of hUC-MSCs for the treatment of POF encourage researchers for further clinical trials, which will overcome the ongoing challenges and make this treatment strategy applicable to the clinic in the near future.

Keywords Premature Ovarian Failure · Ovarian Function · Human Umbilical Cord · Mesenchymal Stem Cells · Infertility